28002643|t|Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma
28002643|a|Heterogeneity of BRAF mutation in melanoma has been a controversial subject. Quantitative data on BRAF allele frequency (AF) are sparse, and the potential relationship with response to BRAF inhibitors (BRAFi) in patients with metastatic melanoma is unknown. We quantitatively measured BRAF AF in a cohort of treatment naïve metastatic melanoma samples by pyrosequencing and correlated with survival data in patients treated with BRAFi as part of their clinical care. Fifty-two samples from 50 patients were analysed. BRAF V600E mutations were detected in 71.1% of samples followed by V600K (25%) and V600R (3.9%). There was a wide range of AF from 3.9% to 80.3% (median 41.3%). In 33 patients treated with BRAFi, there was no difference in overall or progression-free survival when the patients were categorized into high or low AF groups. There was no correlation between AF and degree of response, and no difference in survival based on genotype.
28002643	0	8	Clinical	T080	C0205210
28002643	13	24	therapeutic	T169	C0302350
28002643	25	37	implications	T078	C3146298
28002643	41	54	BRAF mutation	T049	C1511021
28002643	55	68	heterogeneity	T080	C0019409
28002643	72	91	metastatic melanoma	T191	C0278883
28002643	92	105	Heterogeneity	T080	C0019409
28002643	109	122	BRAF mutation	T049	C1511021
28002643	126	134	melanoma	T191	C0278883
28002643	146	167	controversial subject	T078	C1706203
28002643	169	181	Quantitative	T081	C0392762
28002643	182	186	data	T078	C1511726
28002643	190	194	BRAF	T028	C0812241
28002643	195	211	allele frequency	T081	C0017270
28002643	213	215	AF	T081	C0017270
28002643	237	246	potential	T080	C3245505
28002643	247	259	relationship	T080	C0439849
28002643	265	273	response	T032	C0871261
28002643	277	292	BRAF inhibitors	T116,T121	C3838813
28002643	294	299	BRAFi	T116,T121	C3838813
28002643	304	312	patients	T101	C0030705
28002643	318	337	metastatic melanoma	T191	C0278883
28002643	353	367	quantitatively	T081	C0392762
28002643	368	376	measured	T080	C0444706
28002643	377	381	BRAF	T028	C0812241
28002643	382	384	AF	T081	C0017270
28002643	390	396	cohort	T098	C0599755
28002643	400	409	treatment	T169	C0039798
28002643	410	435	naïve metastatic melanoma	T191	C0278883
28002643	436	443	samples	T167	C0370003
28002643	447	461	pyrosequencing	T059	C2732543
28002643	466	476	correlated	T080	C1707520
28002643	482	490	survival	T169	C0220921
28002643	491	495	data	T078	C1511726
28002643	499	507	patients	T101	C0030705
28002643	508	515	treated	T061	C0087111
28002643	521	526	BRAFi	T116,T121	C3838813
28002643	544	552	clinical	T080	C0205210
28002643	553	557	care	T058	C0086388
28002643	569	576	samples	T167	C0370003
28002643	585	593	patients	T101	C0030705
28002643	599	607	analysed	T062	C0936012
28002643	609	643	BRAF V600E mutations were detected	T034	C2698302
28002643	656	663	samples	T167	C0370003
28002643	676	681	V600K	T034	C2985121
28002643	692	697	V600R	T034	C0456984
28002643	732	734	AF	T081	C0017270
28002643	755	761	median	T082	C2939193
28002643	776	784	patients	T101	C0030705
28002643	785	792	treated	T061	C0087111
28002643	798	803	BRAFi	T116,T121	C3838813
28002643	815	828	no difference	T033	C3842396
28002643	832	839	overall	T081	C4086681
28002643	843	868	progression-free survival	T081	C0242792
28002643	878	886	patients	T101	C0030705
28002643	892	903	categorized	T052	C0871968
28002643	909	913	high	T080	C0205250
28002643	917	920	low	T080	C0205251
28002643	921	923	AF	T081	C0017270
28002643	924	930	groups	T078	C0441833
28002643	945	956	correlation	T080	C1707520
28002643	965	967	AF	T081	C0017270
28002643	972	978	degree	T080	C0441889
28002643	982	990	response	T032	C0871261
28002643	996	1009	no difference	T033	C3842396
28002643	1013	1021	survival	T169	C0220921
28002643	1031	1039	genotype	T032	C0017431